By: IPP Bureau
Last updated : May 16, 2025 12:56 pm
Standalone profit from operations for the quarter were Rs. 162 crores
Sanofi India Limited (SIL) declared its financial results for the quarter ended on March 31st, 2025. The Company has delivered net sales growth of 4% on a comparable basis of continuing business.
The successful launch of Soliqua, our best-in-class diabetes drug for the premix segment, continues with a steady growth reinstating confidence and strength in our comprehensive diabetes portfolio.
The company was able to increase its operating profit in Q1-2025 by 27% vs Q1-2024. The improved operating profit was a result of the Company’s focus mainly on lowering expenses through overall operating efficiencies.
The company continues to make good progress on its ‘India for India’ strategy through go-tomarket initiatives, improving operating efficiency and promoting innovation.
“The Company has delivered a strong first quarter performance reflecting Sanofi’s successful strategy for India. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its best-in-class innovative products in India,” Rachid Ayari, Whole Time Director and Chief Financial Officer, said.